AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03193658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I.V drug based multimodal approach
Description: A base low dose opioid of 5mg morphine I.V every 8 hours. Rescue analgesia will be given to the patient if reported a VAS equal or more than 4 in the form of I.V morphine in 2.5mg increments till VAS returns to 4 or less in addition to 1 gm of oral acetaminophen every 6 hours
Study NCT00203944 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral, Development
Study NCT03032601 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl Cysteine
Description: The study consists of two arms. The first arm of this study will receive intravenous and oral NAC, a strong antioxidant that increases brain glutathione, which may be beneficial in MS. NAC, is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It is a common over-the-counter supplement that is also available as an injectable pharmaceutical that protects the liver in cases of acetaminophen overdose. It has the potential to reduce markers of oxidative damage, protect against cell death, and to increase glutathione in blood, which might be useful in preventing oxidative damage in MS patients. The second arm will be a waitlist control receiving standard MS care. It should be noted that both arms will receive standard of care while enrolled into the study.
Study NCT00673725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Locobase® REPAIR
Description: emollient
Study NCT02344797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: The remote ischemic preconditioning procedure is carried out immediately after the induction of regional or general anesthesia. The blood pressure cuff is placed on the upper limb. The cuff is inflated to 200 mmHg resulting in a total occlusion of the blood flow to the limb. After 5 minutes of ischemia the cuff is deflated and the limb is reperfused for 5 minutes. The procedure is carried out 4 times in a row. For patients with systolic blood pressures >185 mmHg, the cuff will be inflated to at least 15 mmHg above the patient's systolic blood pressure.
Study NCT03345888 — intervention group
Intervention type: OTHER
Intervention: predictive power of end-tidal carbon dioxide
Description: end-tidal carbon dioxide predicts resuscitation outcomes
Study NCT02811588 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive ventilation
Study NCT03837119 — intervention group
Intervention type: OTHER
Intervention: pregnancy outcome
Description: descriptive statistics of variables
Study NCT01659346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Variceal Ligation
Description: Endoscopic Variceal Ligation every 3 weeks till eradication.
Study NCT01659346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
Study NCT02060266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will receive a single dose subcutaneously (s.c., under the skin).
Study NCT00606840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: large changes in eating and activity
Description: Behavioral self-regulation interventions to prevent weight gain in young adults.
Study NCT00606840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: small changes in eating and activity
Description: Behavioral self-regulation interventions to prevent weight gain in young adults.
Study NCT05210153 — intervention group
Intervention type: DRUG
Intervention: Sertraline
Description: Drug: Sertraline, a selective serotonin reuptake inhibitor (SSRI), is commercially known as Sidata® or Zoloft® in Serbia. The recommended dose for Major depressive disorder is 100 mg/day. It is recommended to start therapy with 50 mg/day, and in the case of lack of therapeutic effect dose should be increased in 50 mg increments every 2 weeks until intended pharmacological effect is reached. Dose can be increased up to the maximum dose is 200 mg/day. Sertraline is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia), Panic disorder (with or without agoraphobia) and Post-traumatic Stress Disorder by Medicines and Medical Devices Agency of Serbia.~Drug levels are expected to be 50% higher in CYP2C19 poor metabolizers as compared to normal metabolizers, but no specific dosing recommendations are given by the Medicines and Medical Devices Agency of Serbia.
Study NCT02900495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electric nerve stimulation
Description: electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
Study NCT02900495 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcutaneous electric nerve stimulation
Description: electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
Study NCT01966419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ornithine phenylacetate
Description: Ornithine phenylacetate for continuous IV infusion at dose levels predicated on level of hepatic decompensation
Study NCT01966419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo intravenous infusion
Description: Placebo for continuous IV infusion that is visually identical to the experimental product
Study NCT00956631 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Interlaminar Decompression
Description: The MILD® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompression.
Study NCT01671150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endotoxin
Description: Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once
Study NCT01671150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: endotoxin
Description: Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once
Study NCT00393263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimecrolimus and clobetasol
Study NCT00393263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol 0.05% cream
Description: twice daily for three months
Study NCT01732471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan®
Description: Kuvan® (sapropterin dihydrochloride) will be administered orally at a dose of 20 milligram per kilogram per day (mg/kg/day) once daily for 8 days. If there is 30 percent (%) decrease in blood phenylalanine levels from baseline at the end of Day 8, then treatment will be continued at the same dose for further 6 weeks.
Study NCT03493750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral and dental evaluation
Description: Mouth inspection done by a nurse, in order to count missing, coloured, injured teeth, and evaluate dental plaque, halitosis, inflammatory gums, mucosal injuries, low masticatory surface.
Study NCT03824821 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00001656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: tablet; 5-20mg/day; 8 weeks
Study NCT00001656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clozapine
Description: tablet; 12.5-900mg/day; 8 weeks
Study NCT00725101 — intervention group
Intervention type: DRUG
Intervention: Treatment for Fibromyalgia
Description: FM participants starting any new pharmacologic FM agent.
Study NCT03644056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-001
Description: Different IMC-001 dose level for each cohort group (IMC-001 2 mg/kg etc. every 2 weeks)
Study NCT00976209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg
Description: Phenylephrine HCl ER tablets 30 mg taken every 12 hours, twice daily, for 3 days.
Study NCT00976209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg
Description: Phenylephrine HCl IR tablets 10 mg taken every four hours (no more than 6 times daily) for 3 days.
Study NCT03796819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphadenectomy
Description: Patients would undergo routine hepatoduodenal lymphadenectomy at the time of ICC resection
Study NCT01939626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-step medium
Description: This medium will allow in vitro culture of human embryos for 5/6 days
Study NCT01939626 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard culture medium
Description: This culture system needs media change on day 3 of culture.
Study NCT03984227 — intervention group
Intervention type: GENETIC
Intervention: Taking peripheral blood samples
Description: quantitative real-time polymerase chain reaction
Study NCT01920867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RB (Retrobulbar)
Description: Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)
Study NCT01920867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ST (Subtenon)
Description: Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)
Study NCT01920867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IV (Intravenous)
Description: Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)
Study NCT01920867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVIT (Intravitreal)
Description: Intravitreal injection of Bone Marrow Derived Stem Cells (BMSC)
Study NCT01920867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IO (Intraocular)
Description: Intraocular injection of Bone Marrow Derived Stem Cells (BMSC) with vitrectomy prior to intraocular injection. For example, may include larger amount of stem cells in the intravitreal cavity, intraneuronal injections or subretinal injections of stem cells.
Study NCT03796338 — intervention group
Intervention type: DEVICE
Intervention: Sleep Profiler
Description: Patients are observed through a Sleep profiler, routinely used in the intensive care unit (ICU). This device is applied at every patient in the ICU and it acquires EEG, electrooculography, and electromyography from three frontopolar EEG signals.
Study NCT03962231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rotator Cuff Unloading Exercise Program
Description: Patients in this group will perform semi-closed kinetic chain elevation exercises, deltoid reeducation exercises, assisted arm elevation and scapular control exercises.
Study NCT03962231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rotator Cuff Loading Exercise Program
Description: Patients in this group will perform conventional exercises focusing on lateral rotation, medial rotation and arm elevation.
Study NCT04392167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a/LCI-OCT imaging probe
Description: a/LCI and OCT imaging measurements of several locations in the esophagus
Study NCT04392167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophageal biopsy
Description: biopsies of esophageal tissue imaged by a/LCI-OCT probe
Study NCT01882881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy American Control Diet
Description: The Control Diet will be comprised of the same foods as the test diets except for the isocaloric substitution of almonds and/or dark chocolate and cocoa for sources of saturated fat; an approximate 250 kcal substitution. In an effort to keep all the diets consistent (except for the specific foods to be tested), the Control Diet will be slightly higher in fiber (20-25g) and lower in cholesterol (\~250 mg) than the typical consumption practices (15g and 278 mg, respectively).
Study NCT01882881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dark Chocolate/Cocoa Diet
Description: The Dark Chocolate/Cocoa Diet will include a daily hot cocoa beverage containing 11g of natural cocoa powder and 6 pieces of Hershey's Bliss Dark Chocolate (43g of dark chocolate). This amount of dark chocolate and cocoa will allow for the isocaloric substitution with 1.5oz almonds. The total diet will provide \~33% of calories from fat. The SFA (\~12%) in the Dark Chocolate/Cocoa Diet will match that of the Control Diet and be slightly higher than the Almond Diet, however the saturated fat will be comprised largely of stearic acid from the dark chocolate; cholesterol will be ≤200 mg/day. The fiber in the Dark Chocolate/Cocoa Diet will be higher than both the Control and Almond Diets due to the fiber content of the dark chocolate (\~9g).
Study NCT01882881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond Diet
Description: The Almond Diet will include 1.5 oz of almonds daily and provide \~34% of calories from fat. The Almond Diet will be lower in SFA than the Control and Dark Chocolate/Cocoa Diets, containing \~ 8-9% calories from SFA. In addition, both almond containing diets will be slightly higher in MUFA and PUFA than the Control and Dark Chocolate/Cocoa Diets, as a result of the nutrient profile of the almonds. Cholesterol will be ≤200 mg/day; fiber will be increased compared to the Control Diet due to the inclusion of almonds.
Study NCT01882881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dark Chocolate/Cocoa + Almond Diet
Description: This diet is designed to test the additive effects of combining consumption of dark chocolate and cocoa with almonds. The diet will include the same hot cocoa beverage (11g) and dark chocolate pieces (43g) plus 1.5 oz of almonds. Additional high saturated fat foods are removed from the Control Diet to account for both the dark chocolate and almonds. As a result, the total fat will be similar to the other three test diets at \~34-35% and the SFA will match that of the Almond Diet at \~8-9%. The fiber content of this diet will be highest (\~35g); cholesterol will remain ≤200 mg/day.
Study NCT04234269 — intervention group
Intervention type: OTHER
Intervention: Assessment
Description: Evaluation forms will be applied to the patients who meet the inclusion criteria by face to face interview method.The sociodemographic information of the patients and the time taken to answer the questions in the questionnaires will vary according to each patient, but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1 week intervals.
Study NCT01267201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: powder for oral suspension 4 mg/mL single dose (8 mL)
Study NCT01267201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: powder for oral suspension 4 mg/mL singe dose (8 ml)
Study NCT01267201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: tablet 32 mg single dose
Study NCT00291161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partners in Dementia Care
Description: Partners in Dementia Care is facilitated by the VA Dementia care coordinator (VA DCC) that is with the study. The role of the VA DCC includes conducting initial assessments with the subject and caregiver that leads to:~Arranging for further assessment or attention from VA health care system/providers about dementia related concerns or about co-morbid health issues; for example: VA driving evaluation, congestive heart failure medication adherence; Ensuring education is provided about particular health, safety issues; Following up with patient/caregiver on health promoting activities he/she is committed to do; and Sharing care plan actions/outcomes with other VA providers as agreed upon by patient.
Study NCT03621540 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: Using the NeuroConn Plus tDCS device, 2 mA anodal tDCS will be applied to the right dorsolateral prefrontal cortex (F4). 15 s fade in and fade out. Total stimulation time of 1365 s. Cathode over contralateral deltoid muscle.
Study NCT03621540 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Sham mode of the NeuroConn Plus tDCS device with 2 mA stimulation for 45 s at the beginning. Anode over right dorsolateral prefrontal cortex (F4), Cathode over contralateral deltoid muscle. After that, only continuous impedance checking is performed.
Study NCT03621540 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Adaptive working memory training
Description: Adaptive spatial n-back training.
Study NCT03621540 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive working memory training
Description: Adaptive spatial n-back training.
Study NCT04005144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study NCT04005144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given PO
Study NCT00737334 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEGo, BIS, FORE-SIGHT cerebral oximeter
Description: The EEGo monitor, BIS monitor, and FORE-SIGHT cerebral oximeter will be used for cerebral monitoring of all patients. A comparison of the three monitors will be done. For EEGo monitoring, five bipolar electrodes will be placed per International 1020 system. For BIS monitoring, the BIS quattro sensor will be placed on the forehead in usual fashion. For FORE-SIGHT monitoring, the two sensor strips will be placed on the forehead in usual fashion.~All patients will have their ipsilateral Internal Jugular vein cannulated by the surgeon intraoperatively with a 16g IV cannula, through which a Portex multi-orifice epidural catheter will then be placed.
Study NCT04554212 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Flow Restriction Training
Description: Participants will undergo 8 weeks of blood flow restriction training with cuff inflated to 60% occlusion.
Study NCT04554212 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Blood Flow Restriction Training
Description: Participants will undergo 8 weeks of sham blood flow restriction training with cuff inflated to less than 10% occlusion.
Study NCT00801437 — intervention group
Intervention type: DRUG
Intervention: Xalacom
Description: Xalacom 1 drop into the affected eye daily
Study NCT02759887 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tau Pet
Description: Administered during a PET, in small amounts, necessary to create the scan images. Radioactive. The total amount of radiation is about the same that a patient receives from a routine abdominal/pelvis computerized tomography.
Study NCT01236326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoendoscopic single site donor nephrectomy
Description: Patients randomized to this arm will undergo laparoendoscopic single site donor nephrectomy
Study NCT01236326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic donor nephrectomy
Description: Patients randomized to this arm will undergo conventional laparoscopic donor nephrectomy
Study NCT03879057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib/humanized anti-PD-1 monoclonal antibody
Description: humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.
Study NCT01726036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gomco Circumcision Clamp
Description: Neonatal male circumcision utilizing the Gomco Circumcision Clamp
Study NCT01726036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mogen Circumcision Clamp
Description: Neonatal male circumcision utilizing the Mogen Circumcision Clamp
Study NCT00379808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: 10 mg tablet (masked by capsule) daily for 1 month
Study NCT00379808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 lactose-containing capsule daily for 1 month
Study NCT00326170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine (5-aza)
Description: Start at 75 mg/m\^2 subcutaneously daily for 7 days.
Study NCT00326170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 50 mg/kg daily by mouth for 7 days, same days as 5-aza.
Study NCT00326170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA)
Description: 45 mg/m\^2 orally daily (in two divided doses) for 5 days starting on day 3 of the administration of 5-aza and VPA.
Study NCT04076423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual Therapy
Description: DTG + 3TC
Study NCT04076423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple therapy
Description: BIC / FTC / TAF
Study NCT04612777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opening Doors to Recovery
Description: Opening Doors to Recovery (ODR) was created by a large, collaborative group in southeast Georgia as a recovery-oriented approach that navigates clients into services that may in some cases be fragmented and seemingly inaccessible. The team of three Community Navigation Specialists (CNSs) strives to help clients reduce institutional (e.g., hospital, jail) recidivism and embrace recovery. Their process of community navigation is a broader function than traditional case management as it includes mapping out and connecting clients to all available local resources, which requires being embedded in the community. The work of the CNSs benefits from commitments of diverse collaborative ODR partners, including local treatment providers, law enforcement, employers, and housing programs. Each CNS was expected to meet with the client at home or in community settings at least monthly, with the client having contact with at least one CNS weekly.